Climb Bio
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody medicines for immune-mediated diseases.
- Public company
- Wellesley Hills, MA, USUnited States
Climb Bio is a clinical-stage biotechnology company developing monoclonal antibody medicines for immune-mediated diseases.
climbbio.comCrawled Oct 24, 2026
Climb Bio identifies opportunities and pursues outcomes others overlook.
Climb Bio reports that **budoprutug (200 mg)** achieves B-cell depletion, reduces PLA2R antibodies, and induces immunologic remission in patients with primary membranous nephropathy (pMN) after 12 weeks. These Phase 2 results align with earlier Phase 1b findings, demonstrating consistent efficacy in the PrisMN trial.
Oct 2026GlobeNewswireNews article
Climb Bio and Mabworks present clinical data for their therapy **CLYM116/MIL116**, showing **over 90% sustained suppression of free APRIL** for 12 weeks, supporting a **quarterly dosing schedule**. The treatment also achieves a **~70% reduction in Gd-IgA1** at the same interval, with a **33-day half-life**. Results were shared at **ASN Kidney Week 2026**.
Oct 2026GlobeNewswireNews article
Climb Bio (formerly Eliem Therapeutics) completes a corporate rebrand after restructuring its pipeline and conducting mass layoffs. The company shifts its identity as part of broader operational adjustments, though specific details on the pipeline overhaul remain undisclosed.
Oct 2024Fierce PharmaNews article
Climb Bio, formerly Eliem Therapeutics, has rebranded and changed its corporate name. The company operates in the biotechnology sector, focusing on advancing therapeutic solutions. This transition marks a strategic shift in branding and identity for the organization.
Oct 2024GlobeNewswireNews article